FDVKX
Price
$12.48
Change
-$0.03 (-0.24%)
Updated
Sep 20 closing price
VVIAX
Price
$67.77
Change
-$0.05 (-0.07%)
Updated
Sep 20 closing price
Ad is loading...

FDVKX vs VVIAX

Header iconFDVKX vs VVIAX Comparison
Open Charts FDVKX vs VVIAXBanner chart's image
Fidelity Value Discovery K6
Price$12.48
Change-$0.03 (-0.24%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$67.77
Change-$0.05 (-0.07%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FDVKX vs VVIAX Comparison Chart
Loading...
VS
FDVKX vs. VVIAX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FDVKX is a Buy and VVIAX is a StrongSell.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 183B vs. FDVKX (174M). VVIAX pays higher dividends than FDVKX: VVIAX (2.36) vs FDVKX (1.67). FDVKX was incepted earlier than VVIAX: FDVKX (7 years) vs VVIAX (24 years). FDVKX is a more actively managed with annual turnover of: 43.00 vs. VVIAX (10.00). FDVKX has a lower initial minimum investment than VVIAX: FDVKX (0) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 20.40 vs. FDVKX (8.52). VVIAX return over 5 years is better than : 54.20 vs. FDVKX (25.21).
FDVKXVVIAXFDVKX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence7 years24 years-
Gain YTD5.00115.35933%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets174M183B0%
Annual Yield % from dividends1.672.3671%
Returns for 1 year8.5220.4042%
Returns for 3 years-1.2825.00-5%
Returns for 5 years25.2154.2047%
Returns for 10 yearsN/A109.21-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BPRN37.23-0.01
-0.03%
Princeton Bancorp
GEF61.82-0.10
-0.16%
Greif
EVGN2.74-0.10
-3.52%
Evogene Ltd.
ENFN8.42-0.31
-3.55%
Enfusion
SMMT24.56-1.66
-6.33%
Summit Therapeutics